Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Tóm tắt
BAX 855, a pegylated full-length rFVIII with extended half-life, was highly effective in the prevention and treatment of bleeding events. No subjects receiving BAX 855 developed FVIII inhibitory antibodies nor experienced unexpected adverse events.
Từ khóa
Tài liệu tham khảo
Srivastava, 2013, Guidelines for the management of hemophilia., Haemophilia, 19, e1, 10.1111/j.1365-2516.2012.02909.x
National Hemophilia Foundation
National Hemophilia Foundation
Björkman, 2001, Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia., Clin Pharmacokinet, 40, 815, 10.2165/00003088-200140110-00003
Björkman, 2009, Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A., Eur J Clin Pharmacol, 65, 989, 10.1007/s00228-009-0676-x
Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia., N Engl J Med, 357, 535, 10.1056/NEJMoa067659
White, 1997, A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A., Thromb Haemost, 77, 660, 10.1055/s-0038-1656030
Björkman, 2003, Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective., Haemophilia, 9, 101, 10.1046/j.1365-2516.9.s1.4.x
Valentino, 2012, A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management., J Thromb Haemost, 10, 359, 10.1111/j.1538-7836.2011.04611.x
Lillicrap, 2010, Improvements in factor concentrates., Curr Opin Hematol, 17, 393, 10.1097/MOH.0b013e32833c06c6
Fogarty, 2011, Biological rationale for new drugs in the bleeding disorders pipeline., Hematology Am Soc Hematol Educ Program, 2011, 397, 10.1182/asheducation-2011.1.397
Mahlangu, 2014, Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A., Blood, 123, 317, 10.1182/blood-2013-10-529974
Harris, 2003, Effect of pegylation on pharmaceuticals., Nat Rev Drug Discov, 2, 214, 10.1038/nrd1033
Turecek, 2012, BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation., Hamostaseologie, 32, S29
ICH Expert Working Group
Rentz, 2009, Psychometric evaluation of a patient-reported symptom assessment tool for adults with haemophilia (the HAEMO-SYM)., Haemophilia, 15, 1039, 10.1111/j.1365-2516.2008.01955.x
Mannucci, 2013, Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial., Blood, 122, 648, 10.1182/blood-2013-01-479527
Fijnvandraat, 1995, Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels., Br J Haematol, 91, 474, 10.1111/j.1365-2141.1995.tb05325.x
Lalezari, 2014, Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS., Haemophilia, 20, e15, 10.1111/hae.12294
Berntorp, 2014, Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method., Biologics, 8, 115
Blanchette, 2008, Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients., J Thromb Haemost, 6, 1319, 10.1111/j.1538-7836.2008.03032.x
Tarantino, 2004, Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A., Haemophilia, 10, 428, 10.1111/j.1365-2516.2004.00932.x